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Introduction: The management of hyperphosphatemia in patients with chronic kidney 
disease (CKD) is complicated, requiring a multidisciplinary approach that includes dietary 
phosphate restriction, dialysis, and phosphate binders. An improvement in our understanding 
of the underlying mechanisms responsible for phosphate homeostasis has led to the 
development of novel treatment options. 
Areas covered: In this review, we describe key players involved in regulating inorganic 
phosphate homeostasis and their differential role in healthy people and different stages of 
CKD. We also examine the contribution of paracellular and transcellular intestinal absorptive 
mechanisms. Finally, we discuss recent therapeutic approaches for hyperphosphatemia in 
CKD.  We searched PubMed/Medline (up to November 2019) using the following terms: 
chronic kidney disease, dialysis, diet, hyperphosphatemia, NaPi2b, nicotinamide, phosphate 
binder, secondary hyperparathyroidism, tenapanor and vascular calcification.  
Expert opinion: The precise mechanisms regulating intestinal phosphate absorption in 
humans is not yet completely understood. However, it is now well established that this 
process involves two independent pathways: a) active transport (i.e., transcellular route, via 
specific ion transporters) and inactive transport (i.e., paracellular route across tight junctions). 
Dietary phosphate restriction and the use of phosphate-binders can lead to an undesirable 
maladaptive increase in phosphate uptake and promoting of active phosphate transport by 
increased expression of the gastrointestinal sodium-dependent phosphate transporter, NaPi2b. 
Nicotinamide may overcome these limitations through the inhibition of NaPi2b, by improved 
efficacy and reduced phosphate binder use and better compliance. Results from ongoing trials 
in this setting are eagerly awaited. 
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• In healthy adult people, phosphate homeostasis is maintained by the kidneys through 
action of parathyroid hormone and fibroblast growth factor-23 on the sodium-
dependent phosphate cotransporters NaPi2a/c. 
• In progressive kidney disease intestinal absorption and its regulation via vitamin D 
becomes a critical aspect in phosphate management.   
• Passive paracellular transport dominates during normal phosphate availability, while 
the active sodium-dependent transcellular pathways (NaPi2b) become more important 
in cases of low phosphate availability (i.e. dietetic or pharmacological phosphate 
restriction).   
• Tenapanor is a small-molecule sodium–hydrogen exchanger 3 inhibitor that represents 
a new drug candidate with a mode of action that is different from phosphate binders. It 
has already demonstrated robust phosphate-lowering activity in a short-term phase III 
study.  
• Nicotinamide, a modulator of the intestinal NaPi2b expression, has been evaluated in 
several clinical studies in recent years. Low amounts of nicotinamide and oral 






Inorganic phosphorus (present in blood in the form of inorganic phosphate) is a mineral that 
plays an essential role in cell functions, including energy production, membrane transport and 
cell signalling. Approximately 80-85 % of phosphate is localised in bone, 15% intracellularly 
in soft tissues and <1% present in serum [1,2].  
In healthy individuals, the balance between dietary phosphate intake and renal phosphate 
excretion is matched and the flow of phosphate between the skeleton and the extracellular 
phosphate pool is balanced. In CKD patients, phosphate excretion becomes increasingly 
dependent on the actions of phosphaturic hormones such as klotho-fibroblast growth factor-23 
(FGF-23) and parathyroid hormone (PTH). However, these mechanisms cannot compensate 
for a continuous decline in GFR, and increased phosphate (hyperphosphatemia) eventually 
occurs. Hyperphosphatemia is defined as serum phosphate levels of >4.5 mg/dL 
(>1.46 mmol/L). This clinical condition may even be exacerbated through hormonal 
dysregulation of bone metabolism as a further consequence of the loss of kidney function. 
This disturbance in phosphate homeostasis is recognised to be associated with vascular 
calcification [3], and increased cardiovascular (CV) morbidity and mortality [3–7]. Hence, 
appropriate phosphate management is critical in patients with CKD. The optimal range for 
serum phosphate in CKD patients remains controversial. KDOQI guidelines of 2011 suggest 
between 3.5 and 5.5 mg/dL, whereas subsequent 2009 and 2017 KDIGO guidelines [8,9] 
suggest levels towards the normal range. However, even though as many as 90% of patients 
with end-stage renal disease (ESRD) are prescribed phosphate binders, only 30-50% of 
patients reach guideline recommendations [10–16]. This poor achievement of target levels is 
thought to be mainly attributed to poor adherence to dietary recommendations and phosphate 
binders (due to high pill burden, complex intake regimens). Yet, recent advances in our 
understanding of gastrointestinal phosphate absorption suggest that the efficacy of current 
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treatment options could additionally be limited by counteracting pathophysiological changes 
of the phosphate transport machinery in the gastrointestinal tract. 
 
2. The burden of phosphate on CKD outcomes 
Hyperphosphatemia is associated with a significant increase in the risk of CV morbidity and 
mortality, observed in both the general population [17,18] as well as in patients with CKD 
[19–22]. Actually, in pre-dialysis as well as dialysis patients, the risk of CV-related mortality 
is 10-20 times higher than that of the age-matched general population [23,24]. Vascular 
calcifications in patients with CKD are linked to CV-related mortality [3] and consequently, 
novel surrogate markers that estimate the risk for the development of vascular calcification 
have recently been developed and tested in CKD patients [25–27].  
Over 20 years ago Block and colleagues evaluated the distribution of serum phosphate in two 
large databases from the United States Renal Data System; the Case Mix Adequacy Study 
(1990) and the Dialysis Morbidity and Mortality Study Wave 1 (1993) [28]. Patients with a 
serum phosphate >6.5 mg/dL had a 27% increase in the relative risk (RR) of death compared 
to those with serum phosphate ranging from 2.4 to 6.5 mg/dL. This increased risk persisted 
even after considering potential confounders such as coexisting medical conditions, dose of 
dialysis, nutrition status or noncompliance. A few years later, Block reviewed a nationwide 
database of >40,000 hemodialysis patients and documented a strong association between 
higher levels of serum phosphate (>5 mg/dL), and increased risk of death. Later, Kestenbaum 
et al. 2011, observed that serum phosphate levels of >3.5 mg/dL (1.13 mmol/L) were 
associated with significant risk of mortality in CKD patients not on dialysis [22]. More 
recently, a meta-analysis (comprising approximately 200,000 patients) by Hou and colleagues 
was performed on observational studies to assess whether an association exists between 
abnormal serum phosphate level and risk of all-cause mortality in patients with ESRD 
requiring dialysis [29]. Results from this meta-analysis demonstrated that patients with 
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highest or lowest serum phosphate levels were independently associated with increased risk 
(39%) of all-cause mortality (hazard risk = 1.39; 95% CI 1.31-1.47).  
 
3. Players in phosphate metabolism: intestine, kidney and bone  
3.1 Intestinal phosphate absorption 
The mechanism of intestinal phosphate absorption in humans is not yet fully understood. 
However, it is well established that it involves 2 independent pathways: a) active transport 
(i.e., transcellular route, via specific ion transporters) and inactive transport (i.e., paracellular 
route across tight junctions), that mainly works at high phosphate concentrations in the lumen 
and does not show saturation resembling passive diffusion (Figure 1) [30,31].  
The sodium-dependent phosphate cotransporter type 2b (NaPi2b; or SLC34A2) plays a key 
role in active phosphate absorption in the small intestine. In-vivo studies in mice 
demonstrated that as much as 50% of phosphate is absorbed through NaPi2b [32–34], 
pointing towards this cotransporter as an important therapeutic target for the management of 
hyperphosphatemia.  
Recently, Knöpfel et al. 2019  demonstrated that in mouse intestinal segments, intestinal tight 
junctions were shown to be highly permeable to phosphate and acted as a main route for 
passive phosphate absorption in the intestine [35]. The results of these studies suggest that 
when exposed to a normal diet, the paracellular pathway is the dominant route, whereas 
NaPi2b is required when the gradient across the intestinal epithelium is insufficient for 
passive diffusion to occur [32,33,35].  
These two mechanisms and the regulation of different transporters are clearly dependent upon 
dietary phosphate exposure where phosphate restriction and calcitriol contribute to the 
stimulation of NaPi2b mediated phosphate absorption [36]. 
 
3.2 Phosphate handling in the kidney in healthy individuals 
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The kidneys are responsible for the reabsorption of approximately 80% of the inorganic 
phosphate that is filtered by the glomeruli; 60 to 70% resorption in the proximal tubules and 
10 to 20% at distal sites [37]. Within the proximal tubule, phosphate transport from the 
ultrafiltrate across the proximal tubule epithelium is an energy dependent process that requires 
sodium [38]. The three renal sodium phosphate cotransporters, NaPi2a, NaPi2c, and PiT2, are 
all localised on the apical brush border membrane of renal proximal tubule cells and use the 
energy derived from the transport of sodium down its gradient to move inorganic phosphate 
from the luminal filtrate into the cell [39]. Mouse knockout experiments have shown that 
NaPi2a accounts for up to 70% of phosphate transport [40]. In contrast, in humans, genetics 
of inborn forms of renal phosphate wasting have revealed that NaPi2a and NaPi2c may 
contribute to phosphate reabsorption to a similar extent [41,42]. The precise role of PiT2  in 
the regulation of phosphate in humans still remains to be clarified [43]. FGF-23 inhibits 
NaPi2a and 2c thus inhibiting tubular phosphate reabsorption from the primary urine in the 
kidneys [44]. Moreover, it reduces renal calcitriol synthesis and thus inhibits intestinal 
absorption via vitamin D receptor dependent and independent mechanisms.  
Apart from FGF-23, parathyroid hormone (PTH) is a major modulator of renal phosphate 
reabsorption. Rising serum phosphate levels as well as declining levels of calcium and 
calcitriol stimulates PTH synthesis in the parathyroid gland. PTH reduces NaPi2a expression 
in the proximal renal tubule cells by the PTH1 receptor via protein kinase C and protein 
kinase A signalling [45,46]. 
 
3.3 Bone phosphate absorption 
Since approximately 85% of phosphate in humans is localised in bone and teeth, bone health 
plays a central role in phosphate homeostasis [47]. Bone metabolism depends on a balance 
between PTH (parathyroid origin) and calcitriol (renal origin). Bone acts as the main buffer 
for phosphate and calcium and buffering is achieved by the complementary action of these 
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two hormones. It is now recognised that one of the ways bone can influence outcomes in 
CKD is through FGF-23 production. High levels of FGF-23 and phosphate are directly 
proportional to CV events and survival [48].  
Several preclinical studies have explored the mechanisms underlying phosphate regulation in 
the bone. Osteocytes and osteoblasts in bone produce FGF-23 in response to high dietary 
phosphate/hyperphosphatemia, although this response is delayed compared to that of the 
parathyroid glands [49]. In cell culture, phosphate can also be sensed by primary osteoblasts 
and different bone-derived cells. In rat primary mature osteoblasts, extracellular phosphate 
has been shown to increase the production of FGF-23 and augment the stimulatory effect of 
1,25(OH)2 vitamin D3 (calcitriol) on FGF-23 production [50]. FGF-23 transcription levels are 
also increased in a dose and time-dependent manner by phosphate in a rat osteoblastic cell 
line following incubation with calcitriol [51]. It was proposed that this effect was mediated 
via the NADPH-induced production of reactive oxygen species and mitogen-activated protein 
(MAPK)/extracellular signal–regulated kinase (ERK) signalling pathway. Although the 
presence of calcitriol  in culture media can potentiate the effect of high phosphate on FGF-23 
production [50–52], the effect of phosphate may occur (at least partially) without calcitriol. 
This hypothesis is based on the fact that that hypophosphatemia and low plasma FGF-23 in 
mice deficient for the VDR can be normalized by feeding animals a Ca2+ and phosphate rich 
diet [53]. 
 
4. Dysregulation of phosphate homeostasis in CKD  
In individuals with normal renal function, the kidney is mainly responsible for excretion of 
excess phosphate (between 3,700 and 6,100 mg per day) and thus substantially contributes to 
phosphate homeostasis. However, as kidney function deteriorates, the capacity to excrete 
phosphate also declines. Furthermore, serum phosphate levels do not rise markedly until GFR 
falls below 30 ml/min/1.73 m2 [54,55] thanks to a compensatory reduction in tubular 
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resorption, triggered by increased levels of serum FGF-23, PTH, as well as phosphate [56–
58]. However, in stage 4/5 CKD, the kidneys are no longer able to excrete the excess of 
phosphate absorbed by the intestine and hyperphosphatemia almost always develops in those 
receiving dialysis [54]. Physiologically, the roles of FGF-23 and PTH are to maintain 
phosphate balance by stimulating its’ excretion via the kidneys. However, a progressive loss 
of kidney function leads to the increased inability of PTH/FGF23 to enhance fractional 
phosphate excretion. In parallel, renal calcitriol production decreases, bone malfunction and 
development of hyperphosphatemia ensue, because compensatory mechanisms cannot correct 
this imbalance.  
Although the precise mechanisms of this dysregulation are still poorly understood, it is 
recognised that chronic exposure to phosphate (possibly also in parallel with calcium) 
stimulates the release of FGF-23 from bone [59–61]. Thus, it is possible that partial phosphate 
toxicity may occur by a  concomitant increase in FGF-23, particularly in CKD patients where 
large rises in FGF-23 levels occur [62]. In vitro and studies in animal models demonstrate that 
FGF-23 can exert a direct effect on the heart, by inducing left ventricular hypertrophy (LVH) 
[63] in addition to affecting calcium fluxes in cardiomyocytes [64,65], both effects are 
independent of the presence of phosphate. These findings support the idea that FGF-23 may 
participate in inducing consequences of phosphate toxicity, at least on the heart in the CKD 
setting [66]. Therefore, targeting FGF-23 could have benefits. However, this therapeutic 
strategy was not successful in an animal model of CKD where neutralisation of FGF-23 
increased aortic calcification leading to higher mortality rates compared to controls [67]. In 
this study, the observed negative effect was attributed to high phosphate levels. Further 
studies evaluating the effect of FGF-23 neutralization in CKD models with controlled 
phosphate levels and at different stages of CKD will aid our understanding of the role of FGF-
23 in CV disease.  
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In summary, in healthy individuals, inorganic phosphate homeostasis is controlled by active 
and passive pathways of intestinal phosphate absorption, bone metabolism and renal 
excretion, with the latter being modulated by endocrine factors [68].  
Since both the kidney and bone now cease to play a role in phosphate homeostasis in CKD, 
the modulation of intestinal phosphate absorption emerges as a prime target for the treatment 
of hyperphosphatemia [69]. 
  
5. Current options for the management of hyperphosphatemia: dietary and 
pharmacological phosphate restriction  
 
5.1. Dietary phosphate restriction  
Recent KDIGO and KDOQI guidelines suggest that dietary phosphate should be limited 
(daily phosphate intake restricted to 800 to 1000 mg/day and a daily protein intake, as the 
major source of dietary phosphate to 1.2 g/kg body weight) for the treatment of 
hyperphosphatemia in combination with other treatments [9,70,71].    
Among the phosphate lowering strategies, dietary phosphate restriction remains widely 
regarded as an integral component of hyperphosphatemia management [9]. However, this 
strategy is associated with the risk of collateral protein malnutrition [72].  
Since foods high in protein content are also rich in dietary phosphate, dietary phosphate 
restriction mainly involves a reduction in dietary protein intake. This reduction can lead to 
malnutrition and protein-energy wasting, which are strong risk factors for increased mortality 
in patients undergoing maintenance dialysis [73,74].  
There are several important considerations when proposing dietary phosphate restriction. 
First, the bioavailability of phosphate needs to be taken into account and not the phosphate 
content of food alone. In this regard, the source of food (whether it is vegetable or plant based 
compared to animal based) is an important issue to consider. While the so called “good” 
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phosphate sources are mainly derived from plant/vegetable sources, excess “bad” phosphate 
load from food is found in sources that contain phosphate salt additives (processed meats such 
as cooked ham, roast breast turkey/chicken), and some beverages.  
In general, phosphate bioavailability is considerably lower for plant-derived phosphate (e.g. 
vegetables), compared to meat sources [75]. This is likely attributed to a lower phosphate: 
protein ratio and the fact that phosphate derived from vegetables (phytate) is absorbed to a 
lower extent (<50%). In addition, phosphate salts are frequently used as additives to increase 
shelf-life, improve taste and texture of food items. Almost all processed foods contain 
phosphate additives, such as disodium phosphate, monosodium phosphate, and potassium 
triphosphate, to preserve their colour and shelf lives. What is of particular concern is the fact 
that this “bad” phosphate (e.g. processed foods) is almost completely absorbed (from 80-
100%) in the intestine [76,77], compared to only 30-70% by naturally occurring phosphates 
(phosphoproteins, phospholipids, phosphate esters) [78]. In Western diets, achieving adequate 
phosphate restriction is challenging due to the high phosphate content (1-1.6 g/day) [79]. 
In patients with CKD, it is still unclear as to which extent phosphate absorption is modulated 
by dietary phosphate. Pre-clinical studies have allowed researchers to advance our 
understanding on the mechanisms underlying dietary phosphate restriction. 
Aniteli and colleagues evaluated whether short term alterations of dietary phosphate could 
impact levels of hormones involved in phosphate metabolism, expression of sodium-
phosphate cotransporters, apoptosis, and the expression of matrix extracellular 
phosphoglycoprotein in various regions of the small intestine in nephrectomised rats [80]. 
They observed that after 2 days, serum phosphate, phosphate excreted, serum FGF-23, and 
PTH were significantly higher and ionized calcium was significantly lower in the high dietary 
phosphate group compared to the low dietary phosphate group. The expression of NaPi2b and 
PiT-1/2 were increased in the total jejunum mucosa of the low phosphate diet group compared 
with the high phosphate diet group.  
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Collectively, preclinical studies have demonstrated that high phosphate diet appears to be 
linked to low expression of NaPi2b in the intestine, whereas dietary phosphate restriction 
leads to strong upregulation of NaPi2b [39,80–83]. Moreover, many patients with advanced 
stages of CKD develop metabolic acidosis which in turn stimulates the expression and activity 
of NaPi2b [84]. 
Few clinical studies have investigated the effect of diet and phosphate additive replacement 
on hyperphosphatemia [85–87].  A 6-month trial on dialysis patients undertaken in Spain 
compared intensive dietary intervention with usual dietary recommendations. Phosphate 
levels were significantly lower (multivariate-adjusted difference 0.93 mg/ dl; 95% CI 0.34 - 
1.52; p=0.003) in the experimental group with lower prevalence of hyperphosphatemia vs. 
controls (49% vs. 82%) [87]. The effect of replacing foods high in phosphate additives with 
food without additives was evaluated in two randomized trials [85,86]. In the first trial by de 
Fornasari and Dos Santos Sens, 2017, the intervention group received verbal and written 
counselling on how to replace processed foods that have phosphorus additives (e.g. long life 
dairy products such as milk or yoghurts, processed meats such as ham turkey and salami, 
breads, biscuits, cakes, crackers and beverages such as dark cola, black tea) with foods of 
similar nutritional value without these additives (e.g. plain yoghurts, minas cheese, home 
cooked meats, homemade breads, biscuits and cakes, homemade ice tea and apple juice). The 
control group only received nutritional advice before the study. In the second study, Sullivan 
and colleagues demonstrated that it was possible to achieve a small but clinically significant 
reduction in serum phosphorus levels in hemodialysis patients after receiving education on 
avoiding foods with phosphorus additives when purchasing groceries or visiting fast food 
restaurants. Both studies observed significant reductions in serum phosphate concentrations 
and hyperphosphatemia after a period of 3 months [85,86]. 
In summary, apart from a higher risk of malnutrition, an important limitation of dietary 
phosphate restriction is associated with a compensatory upregulation of the NaPi2b 
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expression levels, which in turn enhances active phosphate transport. This maladaptive 
response potentially limits the efficacy of dietary restriction as a strategy in lowering serum 
phosphate, as the remaining phosphate from food may be absorbed more efficiently by the 
transcellular pathway.  
 
5.2 Pharmacological approaches to reduce phosphate burden in ESRD: 
Oral phosphate binders represent the mainstay in the treatment of hyperphosphatemia in 
ESRD patients. They effectively reduce the absorption of dietary phosphate in the 
gastrointestinal tract through the exchange of the anion phosphate with an active cation (e.g. 
calcium, lanthanum, magnesium, aluminium, iron) and sevelamer to form a nonabsorbable 
compound that is subsequently excreted with feces.  
In-vivo studies have further developed our understanding of the mechanisms by which 
phosphate binders may act on phosphate transport processes.  
Schiavi et al. 2012, used adenine to induce uremia in both NaPi2b-deficient and wild-type 
mice [88]. NaPi2b-deficient uremic mice were found to have significantly lower levels of 
serum phosphate and attenuation of FGF-23 compared with wild-type uremic mice. NaPi2b-
deficient mice treated with the phosphate binder sevelamer carbonate were further shown to 
have decreased phosphate levels. Uremic mice were characterised by high turnover of renal 
osteodystrophy and sevelamer significantly decreased osteoclasts number and rate of mineral 
apposition in NaPi2b-deficient mice. However, sevelamer had no effect on bone formation or 
rate of mineral apposition in wild-type mice while it increased the expression of NaPi2b in the 
uremic mice. The observation that sevelamer has an impact on osteoclast numbers and 
mineral apposition only in NaPi2b-deficient mice but not in wild-type animals, supports the 
idea that inhibition of NaPi2b expression might enhance efficacy of therapies targeting 
luminal phosphate availability in a combination therapy approach. 
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More recently, Kaesler and colleagues examined the effect of nicotinamide alone and in 
combination with magnesium carbonate (MgCO3) in CKD mice (nephrectomised and 
subjected to a 7-week high-phosphate diet) [89].  While MgCO3 treatment alone was observed 
to increase intestinal expression of the NaPi2b and Pit-1 and decrease calcification severity, 
nicotinamide alone increased soft tissue and vascular calcification. Nicotinamide in 
combination with MgCO3 normalized the increased levels of NaPi2b and Pit-1 expression and 
decreased calcification severity. As pointed out by the authors of this study, major 
physiological differences exist between mice and humans with regard to intestinal phosphate 
transport. In humans, NaPi2b is mainly located in the duodenum and jejunum, whereas in 
mice it is mainly located in the ileum [90]. The dose of nicotinamide used in this in-vivo 
study was approximately 6-fold higher compared with clinical trials. For these reasons, 
caution is needed when extending findings from this study to the clinical situation. 
Taken together, findings from Schiavi et al. 2012 and Kaesler et al. 2019 show that in 
experimental models phosphate binder intake is characterized by a compensatory upregulation 
of NaPi2b, pointing towards the use of a phosphate binder in combination with a NaPi2b 
inhibitor. 
 
6. Novel treatment options 
In clinical practice, as many as 50% of dialysis patients still present with persistently elevated 
phosphate levels, despite dietary and pharmacological phosphate restriction [91]. Thus, there 
is a substantial gap between guideline recommendations and clinical practice. As described 
above, dietary and pharmacological phosphate restriction are characterized by 
pathophysiological maladaptations that could facilitate active phosphate absorption across the 
brush border membrane of the gastrointestinal tract, and thus limit the pharmacological 
efficacy of these current standard treatment options. Novel drug candidates that target 
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different elements of the intestinal phosphate transport system are currently under 
development and may provide further prospects for improved phosphate control. 
 
6.1 Targeting renal phosphate excretion 
Renal phosphate reabsorption is mediated to a large extent by the NaPi2a (SLC34A1) 
phosphate transporter located in the proximal tubule. In analogy to inhibition of renal glucose 
reabsorption by SGLT2 inhibitors, inhibition of renal phosphate transporters may lower 
phosphate burden in patients with earlier stages of CKD (i.e. those with sufficient GFR to 
filter relevant amounts of phosphate).  Inhibitors of NaPi2a have been developed by several 
companies and are in preclinical testing [92,93]. The PF-06869206 inhibitor induced transient 
phosphaturia in normal mice and mice with 5/6 nephrectomy lowering plasma phosphate 
levels [94]. The inhibitor is also effective in increasing renal phosphate excretion in mice 
lacking FGF23 or in the adenine-induced CKD mouse model [95]. Similarly, the BAY767 
inhibitor also induced phosphaturia and reduced vascular calcifications in a rat model with 
blocked FGF23 signalling [93]. Thus, inhibition of renal phosphate reabsorption may be a 
viable option to lower phosphate in those patients with partly preserved GFR. 
 
6.2 Targeting of paracellular intestinal phosphate absorption 
Tenapanor is a minimally absorbed small-molecule inhibitor of the sodium/hydrogen 
exchanger isoform 3 (NHE3) that was originally designed to inhibit the intestinal absorption 
of sodium [96]. Actually, tenapanor was shown to be able to reduce extracellular fluid 
volume, LVH, albuminuria and blood pressure in salt fed nephrectomized rats [96]. In a 
subsequent in-vivo study, it was shown that tenapanor could reduce the intestinal absorption 
and urinary excretion of phosphate, while fecal phosphate excretion increased [97]. Recently, 
the mechanism of tenapanor-mediated inhibition of phosphate intestinal absorption has been 
characterised and it is thought to be independent of SLC34 and SLC20 cotransporters [98]. 
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The  mechanism by which tenapanor reduces gastrointestinal phosphate uptake has been 
investigated in in vivo studies in rodents and translational experiments with human small 
intestinal stem cell–derived enteroid monolayers to model ion transport physiology. 
Tenapanor decreases passive paracellular phosphate absorption due to the modulation of tight 
junctions. At the same time, tenapanor was shown to be able to exert a modest decrease in 
NaPi2b expression. Still, the reduction of intestinal phosphate absorption is predominantly 
based on reduction of passive paracellular phosphate flux, an effect mediated exclusively via 
on-target NHE3 inhibition. When tenapanor was administered to patients undergoing 
hemodialysis, the increases of both serum phosphate and FGF-23  were prevented in a dose-
dependent manner compared to placebo [99–101]. However, to date, we do not know whether 
tenapanor offers any added value compared to current standard of care (i.e. phosphate 
binders). Information is also lacking as to whether tenapanor may also act synergistically 
when used in combination with phosphate binders. 
 
6.3. Targeting of transcellular intestinal phosphate absorption  
6.3.1 NaPi2b inhibitor ASP3325 
ASP3325 is a novel small-molecule NaPi2b-specific inhibitor that was demonstrated to be 
safe and effective in reducing systemic phosphate levels in a rat model of adenine-induced 
renal failure as well as in normal rats fed a high-phosphate diet [102]. A recent clinical trial 
by Larsson and colleagues failed to show that ASP3325 can alter urinary or fecal phosphate 
excretion in normal healthy individuals or reduce serum phosphate levels in ESRD patients 
[103]. The lack of efficacy of ASP3325 in this trial also contrasts other preclinical studies  
demonstrating a marked reduction in hyperphosphatemia in different rat models [32,102].  
Differences in intestinal phosphate transport between rat and human species may possibly 
explain the negative clinical findings observed by Larsson and colleagues [103].  A dose 
ranging trial to assess pharmacokinetics, safety and tolerability of ASP3325 has also been 
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performed in hemodialysis patients with hyperphosphatemia in Japan (NCT02510274), 
however results from this trial are not yet available[104].   
 
6.3.2 Pan-transporter inhibitors 
EOS789 targets the intestinal NaPi2b phosphate transporter as well as the Pit1 and Pit2 
transporters which are also located in the intestine. The role of Pit1 and Pit2 in intestinal 
phosphate absorption is not fully clarified. In healthy subjects, one week of EOS789 reduced 
urinary phosphate excretion in a dose-dependent manner, while increasing fecal phosphate 
content [105,106]. In a small group of patients on hemodialysis, EOS789 decreased intestinal 
phosphate absorption when given alone or in combination with a phosphate binder. While 
acute EOS789 appears to be well tolerated, no data are available on the long-term efficacy 
and safety of this molecule. 
 
6.3.3 Nicotinamide 
Mode of action and preclinical evidence 
While the exact mode of action still remains to be fully understood, preclinical studies have 
suggested that nicotinamide reduces hyperphosphatemia in a NaPi2b-dependent manner.  
Over 20 years ago, Katai et al. 1999 were the first to show that nicotinamide inhibits active 
intestinal phosphate absorption. Rats were treated with either nicotinamide (4 mmoL/kg) or 
saline [37]. While the sodium-independent phosphate transporter was unaffected by 
nicotinamide, the sodium-dependent phosphate transport was reduced two-fold following 
nicotinamide treatment (p<0.01). In additional experiments, poly RNA isolated from the 
jejunum of animals treated either with saline or nicotinamide was injected into Xenopus 
oocytes, and the sodium-dependent phosphate transport capability was assayed. Oocytes 
injected with RNA isolated from control animals displayed a two-fold increase in phosphate 
transport vs. water-injected oocytes. In contrast, the injection of RNA isolated from the 
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jejunum of nicotinamide-treated animals did not change the sodium-dependent phosphate 
transport level. This study showed that nicotinamide decreases intestinal sodium-dependent 
phosphate transport and that nicotinamide lowers the level of functional sodium/phosphate 
cotransporter mRNA in the rat jejunum. 
Eto et al. (2006) later evaluated the effects of nicotinamide (4 mmoL/day for six days) on 
serum phosphate concentration, intestinal phosphate absorption and urinary phosphate 
excretion in a rat model of adenine-induced chronic kidney failure [107]. While serum 
phosphate concentrations strongly increased in control animals, phosphate concentrations in 
animals treated with nicotinamide remained unchanged. Further experiments using 
radiolabelled phosphate showed that nicotinamide did not affect urinary excretion but 
inhibited intestinal absorption. Along these lines NaPi2b-protein expression was reduced in 
the brush border membrane of the jejunum. 
In a third preclinical study, the functional importance of NaPi2b in the context of 
nicotinamide-mediated inhibition of intestinal phosphate absorption was demonstrated by 
Sabbagh et al.2009 [32]. Wild-type and NaPi2b-deficient mice were fed with a low phosphate 
diet for 7 days. Following a subsequent phosphate bolus administration, serum phosphate 
concentration was shown to be strongly increased in wild-type animals. Instead, in NaPi2b-
deficient animals only a moderate increase was observed, leading to significantly lower serum 
phosphate concentrations compared to wild-type animals. The effect seen in wild-type 
animals could be restored by a prior treatment with nicotinamide while nicotinamide-pre-
treatment had no effect in NaPi2b-deficient animals. These results indicate that nicotinamide 
is dependent upon functional NaPi2b in order to reduce a hyperphosphatemic response 
following an acute phosphate bolus administration. Nicotinamide also reduces renal 
phosphate transport and NaPi2a/c expression in rat models[108,109]. 
Collectively, findings from these animal studies point towards the possibility that 




The effect of nicotinamide in predialysis patients 
Clinical studies have been undertaken in predialysis patients to examine the efficacy of 
nicotinamide administered as monotherapy [110] or in combination with a phosphate binder 
[111]. 
First, a randomised controlled trial by Malhotra and colleagues evaluated the effect of 1,500 
or 2,000 mg/d extended-release niacin (i.e. nicotinic acid, a chemical substance closely related 
to nicotinamide), as monotherapy vs. placebo on plasma phosphate in 352 patients with CKD 
stages 3 and 4 [110]. Patients that were assigned to niacin showed a decrease in serum 
phosphate from 3.4 to 3.3 mg/dL compared with an increase from 3.4 to 3.6 mg/dL in the 
placebo group. Although statistically significant (P<0.01), the relevance was questionable as 
niacin treatment did not result in changes of the CKD-MBD markers FGF-23, PTH, calcium 
or vitamin D over a period of 3 years.  
The effect of nicotinamide administered alone and in combination with a phosphate binder 
was also evaluated in predialysis patients. COMBINE was a randomized, placebo controlled 
trial involving 205 patients with stage 3b/4 CKD and the effect of nicotinamide (750 mg twice 
daily), lanthanum carbonate (1000 mg thrice daily), or both, versus placebo over 12 months 
was evaluated [111]. It was observed that neither drug (alone or in combination), reduced 
serum phosphate or FGF-23 significantly compared to the placebo arm or versus baseline 
concentrations.  
Taken together, results from these clinical studies suggest that nicotinamide administered as 
monotherapy or combined with a phosphate binder appears to have only a limited impact on 
mineral and bone disease in predialysis patients.  
 
The effect of nicotinamide as monotherapy in dialysis patients 
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Takahashi and colleagues were the first to show the phosphate-lowering effect of 
nicotinamide in hemodialysis patients [112]. Sixty-five hemodialysis patients with a serum 
phosphate levels >6.0 mg/dL after a 2-week washout of calcium carbonate participated in the 
study. Nicotinamide was administered for 12 weeks at a starting dose of 500 mg/day and 
increased by 250 mg/day every 2 weeks until serum phosphate levels were <6.0 mg/dL. A 2-
week post-treatment washout period followed the cessation of nicotinamide. The mean serum 
phosphate concentration was 5.4±1.5 mg/dL at the beginning of the pre-treatment washout 
phase. During washout of the previous phosphate binder serum phosphate rose to 
6.9±1.5 mg/dL and decreased again to 5.4±1.3 mg/dL during the 12-week nicotinamide 
treatment (P<0.0001). At the end of this treatment phase, the mean daily nicotinamide dose 
was 1,080±370 mg. Median serum iPTH levels decreased from the maximum 230 (90.8 to 
582) pg/mL to 150 (57.6 to 518) pg/mL after the 12-week nicotinamide treatment (P<0.05). 
More recently, in the NICOREN trial, Lenglet et al. 2017 randomized 100 patients on chronic 
hemodialysis to either open-label oral nicotinamide (0.5–2 g per day) or open-label sevelamer 
hydrochloride (3.2–9.6 g per day) for 24 weeks to examine noninferiority and safety. Before 
randomization, all patients underwent a washout period to remove the previous phosphate 
binder [113].The mean daily nicotinamide and sevelamer doses were 1,300 mg and 8,600 mg, 
respectively, at the end of the 24-week randomized treatment period. Both nicotinamide and 
sevelamer decreased serum phosphate to a similar extent, yielding significantly lower serum 
levels at week 24 compared to the respective baseline levels (from 2.3±0.5 to 1.7±0.5 mM, 
p<0.001) for sevelamer-group and for the nicotinamide –group (from 2.1±0.4 to 1.8±0.5 mM, 
p<0.01). However, non-inferiority was not reached, likely due to the lower number of patients 
included in the study than planned [113]. iPTH did not notably change in both treatment 
groups. With respect to FGF23 levels, differential changes of median levels were observed 
(decrease in sevelamer -group, increase in nicotinamide -group). These data are difficult to 
interpret due to a considerable number of missing values already at baseline (16% in patient 
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groups) and different attrition rates. The high discontinuation rate was mainly attributed to the 
high frequency of adverse events in the nicotinamide group (24%) versus patients in the 
sevelamer group, (4%, p=0.05). However, patients previously treated with sevelamer were not 
excluded from the study, suggesting possible selection bias favouring tolerability with 
sevelamer. In conclusion, the results of these two open-label studies suggest that daily 
nicotinamide doses of at least 1,000 mg are needed in a monotherapy setting in order to 
achieve a phosphate reduction comparable to phosphate binders. Thus, nicotinamide alone is 
most likely not able to provide a clinically relevant benefit compared to standard treatment 
with phosphate binders. 
 
Use of nicotinamide in combination with phosphate binder in dialysis patients 
To address the potential use of nicotinamide in combination with oral phosphate binders, 
several smaller studies performed in dialysis patients have been undertaken in the last ten 
years.  
Three double-blind placebo-controlled studies have evaluated the effect of nicotinamide 
administered in combination with phosphate binders (calcium-based, sevelamer, and 
lanthanum carbonate) in adult dialysis patients. Nicotinamide was tested at daily doses 
between 500 and 1,500 mg in forced titration regimens. All three studies demonstrated a rapid 
reduction of the serum phosphate concentration for daily doses of 500 mg. Forced titration 
was associated with a further reduction of serum phosphate. However, this additional effect 
was less pronounced than the immediate effect seen at 500 mg per day. 
Over 10 years ago, Cheng examined the effect of 8 weeks of nicotinamide (500 to 1500 mg/d) 
vs. placebo in 33 dialysis patients [114]. Serum phosphate levels decreased significantly from 
6.26 to 5.47 mg/dL with nicotinamide but not with placebo (5.85 to 5.98 mg/dL).  
A further randomized, double blind, placebo controlled trial also evaluated the effect of 
nicotinamide to reduce serum phosphate levels in adult peritoneal dialysis patients with 
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hyperphosphatemia over 8 weeks [18]. Patients were randomized to nicotinamide (250 mg 
twice daily, with titration to 750 mg twice daily) or placebo. Phosphate binders, active 
vitamin D, and cinacalcet remained constant for the duration of the study. During the first two 
weeks (500 mg/d) the mean serum phosphate levels has decreased from 5.9±0.6 mg/dL to 
5.1±1.0mg/dL in the nicotinamide-group and remained essentially unaffected in the placebo-
group (5.5±0.5 mg/dL at baseline, 5.4±0.7 mg/dL at week 2). At the end of the randomized 
treatment phase (week 8), serum phosphate levels were 5.2±0.9 mg/dL and 5.9±0.4 mg/dL in 
the nicotinamide- and placebo-group, respectively, with an absolute difference in change 
between groups of 1.1 mg/dL (p=0.037).  
In a trial conducted in Iran by Shabazian and colleagues, 48 hemodialysis patients with 
hyperphosphatemia were randomly (1:1) assigned to nicotinamide or placebo [115]. In 
addition to double-blinded intake of the study medication, patients remained on their prior 
calcium carbonate dose that was to be kept constant throughout the study period. 
Nicotinamide was administered at 500 mg/day for 4 weeks and a further four weeks at 1,000 
mg/day. In the placebo-group, the mean phosphate levels were 5.8 mg/dL, 6.1 mg/dL, and 
5.6 mg/dL at baseline, week 4, and week 8, respectively. No statistically significant overall 
changes were observed for serum phosphate in this treatment group. In the nicotinamide 
group, the mean phosphate levels rapidly decreased from 5.9±0.58 mg/dL to 4.77±1.43 mg/dl 
in week 4 (p=0.002 compared to baseline) and only slightly decreased further to 4.66±1.06 
mg/dL in week 8 (p=0.000 compared to baseline, not significant compared to week 4). In 
contrast, the authors reported an apparent dose-dependent reduction of the mean platelet count 
from 216.5±64.8/nL at baseline to 192.3±65.6/nL at week 4 (not significant) and 
168.8±57.0/nL at week 8 (p<0.001). Between-subjects repeated measures analysis of variance 
was also applied to compare changes in variables for the three time points in the nicotinamide 
vs. placebo group. Statistically significant differences were observed between the placebo and 
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nicotinamide groups respectively for phosphorus (5.65 vs. 4.66 mg/dL at 8 weeks, ANOVA; 
p=0.001).  
The use of nicotinamide in combination with phosphate binder has also been evaluated in a 
pediatric population [116]. In children undergoing hemodialysis, nicotinamide (100 mg two or 
three times daily) plus calcium-based phosphate binders, or calcium-based phosphate binders 
alone was evaluated over the course of 6 months. Serum phosphate decreased from 6.9±1.6 
mg/dL at baseline to 5.1±0.9 mg/dL at month 6 (p<0.0001) in the group receiving 
nicotinamide and phosphate binders, and statistically significant increase was observed in 
those receiving phosphate binders alone (baseline, 7.7±1.9 mg/ dL; month 6, 8.1±1.4 mg/dL; 
p<0.0001; between-group comparison, p=0.001). 
Taken together, these studies indicate that the addition of low doses of nicotinamide (e.g. 
500 mg/d) to oral phosphate binders may be a promising future option to improve phosphate 
control in dialysis patients. Importantly, in this setting the risk for apparent dose-dependent 
side effects (e.g. gastrointestinal disturbances, reduction of platelet numbers) should be 
considerably lower compared to a monotherapy with daily doses of 1,000 mg and higher.  
 
7. Conclusion 
Dietary phosphate restriction and use of phosphate binders represent the main treatment 
strategies for hyperphosphatemia in ESRD patients. Growing evidence from animal 
experiments suggests that these current treatment options may be associated with maladaptive 
responses of the intestinal phosphate transport machinery that could add to clinically 
insufficient phosphate control in many patients. Tenapanor, a small-molecule NHE3 inhibitor, 
represents a new drug candidate with a mode of action that is distinct from phosphate binders 
and it has already demonstrated robust phosphate lowering activity in a short-term phase III 
study [100]. Nicotinamide, a modulator of the intestinal NaPi2b expression, has been 
evaluated in several clinical studies in recent years. Considering all available data, low 
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amounts of nicotinamide and oral phosphate binders may act synergistically to improve 
phosphate control in dialysis patients. 
 
8. Expert opinion  
Serum phosphate levels remain elevated in approximately half of dialysis patients even after 
they have undergone dietary and/or pharmacological phosphate restriction. Therefore, a 
substantial gap still exists between targets specified in guideline recommendations and what is 
seen in daily clinical practice. A better understanding of the molecular mechanisms involved 
in phosphate transport and its regulation will allow the development of novel therapeutic 
agents that can be used to manage hyperphosphatemia in the CKD setting. To date, it is 
recognised that in addition to active transport, the intestine is also known to absorb luminal 
phosphate through the passive pathway. However, although this mechanism was proposed 
over 50 years ago in in-vivo studies, its molecular identity still remains to be fully elucidated 
(Figure 1). Actually, the vast majority of information available on the potential mechanisms 
that occur in the intestine is limited to the active component. Current therapeutic options to 
manage hyperphosphatemia in CKD patients (dietary phosphate restriction as well as 
phosphate binders), aimed to decrease the uptake of dietary phosphate across the intestinal 
epithelia, are still suboptimal therapies. Therefore, it is paramount that an extensive molecular 
characterization of the mechanisms regulating phosphate intestinal absorption in CKD is 
achieved. We have identified several unmet needs that still remain to be addressed in 
hyperphosphatemia (Box 1). 
One of the main weaknesses of phosphate binders is the fact that their efficacy can be greatly 
hampered by a lack of adherence [117,118]. This is likely attributed to the high burden of side 
effects experienced and number of pills consumed in these patients [119]. This is a real 
concern, since reported rates of non-adherent patients to phosphate binders on average are 
close to 50% [118,120].  
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High-quality evidence for the long-term benefits of lanthanum or iron-based binders 
compared vs. placebo or calcium-based treatment is not yet available from current research. 
The 2017 LANDMARK trial comparing lanthanum carbonate vs. calcium carbonate among 
2309 patients should soon have results and may provide a clearer idea of the effects of 
lanthanum carbonate in individuals with ESRD on dialysis [121].  
In dialysis patients, the “add-on” approach using nicotinamide in combination with phosphate 
binders and/or phosphate dietary restriction, may be attractive, particularly in patients where 
dietary restriction and/or phosphate binder therapies alone do not achieve normal phosphate 
levels. In these patients, management of phosphate concentration and timing of phosphate 
exposure would favour the combined use of a phosphate binder and phosphate transport 
inhibitor [122]. 
Ketteler and colleagues recently evaluated the pharmacokinetic characteristics and short-term 
tolerability of a novel modified release formulation of nicotinamide (NoPhos) at a dose range 
between 250 and 1,000 mg) for once daily oral route administration [123]. The authors 
concluded that NoPhos offers advantageous pharmacological properties compared to 
immediate release formulations and at the same time ensures a solid phosphate lowering 
activity after once daily intake. This novel modified release preparation NoPhos represents a 
novel therapeutic option for haemodialysis patients with hyperphosphatemia. 
Data derived from long-term trials for NoPhos as add-on to phosphate binders are also 
currently unavailable. Results from a phase III multicenter study (EudraCT Nr.: 2013-000488-
95) evaluating the therapeutic effect of nicotinamide as add-on approach to phosphate binder 
in more than 700 hemodialysis patients are eagerly awaited.  To date, long-term trials in larger 
patient cohorts are still needed for tenapanor as it is unclear whether tenapanor can provide an 
improvement in phosphate control compared to phosphate binders [124].  
One of the difficulties encountered in clinical trials examining the effect of phosphate binders, 
is the fact that often patients in these studies have multiple comorbidities. This frequently 
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leads to difficulty in trials aiming to observe a reduction in phosphate. Due to the link 
between hyperphosphatemia and vascular calcification [3], researchers have developed an in 
vitro blood test that provides a propensity score to extra-skeletal calcification. The test, named 
maturation time (T50) measures calciprotein particles  (CPP) in serum and is based on the 
difference in timing of the change of calcium phosphate–containing primary CPP to 
hydroxyapatite–containing secondary CPP. 
High serum calcification propensity (i.e., reduced serum T50), defined as the overall tendency 
to calcify, is associated with the progressive aortic stiffening, a predictor of poor survival. 
This biomarker has now been tested in a cohort of cohort of 184 patients with stage 3/4 CKD. 
Baseline T50 was found to be independently associated with aortic pulse wave velocity in all 
randomized patients, while in about 50% of CKD patients, progressive aortic stiffening was 
associated to T50 after 30 months of follow-up. Furthermore, the lowest T50 was closely 
dependent on serum phosphate levels and serum fetuin-A levels [26]. Although few studies 
have been undertaken to date examining the use of T50 as a surrogate marker of vascular 
calcification, this biomarker warrants further investigation as a pre-specified endpoint in trials 
examining benefit of potential treatment approaches in patients with hyperphosphatemia.  
Due to limitations in existing studies and a lack of evidence for specific clinical questions, 
further studies will hopefully yield stronger evidence on the effects of different phosphate 
binders in CKD, facilitating improved therapeutic management of these difficult to treat 
patients.  
 
9. Literature search  
We searched PubMed/Medline and clinical trials.gov (up to November 2019) for published 
and unpublished studies using the following terms: chronic kidney disease, dialysis, diet, 
hyperphosphatemia, NaPi2b, nicotinamide, phosphate binder, secondary hyperparathyroidism, 
tenapanor and vascular calcification. Studies were excluded that were not published English, 
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German or Italian language, in addition to hand selected case studies; abstracts; letters and 
reviews. Duplicate articles, including articles that were not related or not relevant to 
hyperphosphatemia or the topic discussed, were also removed. 
 
Acknowledgements 
Authors wish to thank Colin Gerard Egan, PhD (CE Medical Writing, Pisa Italy) for editorial 
assistance in the writing of this review. Work in the laboratory of CAW has been supported 
by the Swiss National Science Foundation and the National Center of Competence in 
Research NCCR Kidney.CH. 
 
Disclosures 
MC declares advisory and/or lecture fees from Medice, Amgen, AbbVie, Shire, Vifor-
Fresenius Pharma and Baxter. CAW has received honoraria from Medice and Bayer. MK has 






Papers of special note have been highlighted as either of interest (•) or of considerable interest 
(••) to readers 
[1]  Spasovski G, Massy Z, Vanholder R. Phosphate metabolism in chronic kidney disease: 
from pathophysiology to clinical management. Semin Dial. 2009;22:357–362. 
[2]  Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. 
Kidney Int. 2008;74:148–157. 
[3]  Cozzolino M, Ciceri P, Galassi A, et al. The Key Role of Phosphate on Vascular 
Calcification. Toxins (Basel). 2019;11. 
[4]  Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, 
cardiovascular events, and hospitalization. N. Engl. J. Med. 2004;351:1296–1305. 
[5]  Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and 
cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–
352. 
[6]  Vervloet MG, Sezer S, Massy ZA, et al. The role of phosphate in kidney disease. Nat 
Rev Nephrol. 2017;13:27–38. 
[7]  Askar AM. Hyperphosphatemia. Saudi Med J. 2015;36:13–19. 
[8]  Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. 
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and 
treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney 
Int. Suppl. 2009;S1-130. 
[9]  Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO 
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: 
what’s changed and why it matters. Kidney Int. 2017;92:26–36. 
[10]  Djukanović L, Dimković N, Marinković J, et al. Association between Hemodialysis 
Patient Outcomes and Compliance with KDOQI and KDIGO Targets for Mineral and 
Bone Metabolism. Nephron. 2016;132:168–174. 
[11]  Arenas MD, Alvarez-Ude F, Gil MT, et al. Application of NKF-K/DOQI Clinical 
Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and 
their effects on outcomes and quality standards in three haemodialysis units. Nephrol. 
Dial. Transplant. 2006;21:1663–1668. 
[12]  Craver L, Marco MP, Martínez I, et al. Mineral metabolism parameters throughout 
chronic kidney disease stages 1-5--achievement of K/DOQI target ranges. Nephrol. Dial. 
Transplant. 2007;22:1171–1176. 
[13]  Lebner AC, Beard KM, Soroka SD, et al. Interprovincial differences in the achievement 




[14]  Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism 
and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760–771. 
[15]  Palomares I, Ramos R, Martin-Malo A, et al. Compliance with mineral metabolism 
targets in haemodialysis patients: moving backwards? Blood Purif. 2013;36:122–131. 
[16]  Pronai W, Rosenkranz AR, Bock A, et al. Management of secondary 
hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or 
without active vitamin D in Austria and Switzerland - the observational TRANSIT 
Study. Wien. Klin. Wochenschr. 2017;129:317–328. 
[17]  Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium 
levels to the incidence of cardiovascular disease in the community. Arch. Intern. Med. 
2007;167:879–885. 
[18]  Foley RN, Collins AJ, Herzog CA, et al. Serum phosphorus levels associate with 
coronary atherosclerosis in young adults. J. Am. Soc. Nephrol. 2009;20:397–404. 
[19]  Da J, Xie X, Wolf M, et al. Serum Phosphorus and Progression of CKD and Mortality: 
A Meta-analysis of Cohort Studies. Am. J. Kidney Dis. 2015;66:258–265. 
[20]  McGovern AP, de Lusignan S, van Vlymen J, et al. Serum phosphate as a risk factor for 
cardiovascular events in people with and without chronic kidney disease: a large 
community based cohort study. PLoS ONE. 2013;8:e74996. 
[21]  Fukagawa M, Kido R, Komaba H, et al. Abnormal mineral metabolism and mortality in 
hemodialysis patients with secondary hyperparathyroidism: evidence from marginal 
structural models used to adjust for time-dependent confounding. Am. J. Kidney Dis. 
2014;63:979–987. 
[22]  Kestenbaum B, Katz R, de Boer I, et al. Vitamin D, parathyroid hormone, and 
cardiovascular events among older adults. J. Am. Coll. Cardiol. 2011;58:1433–1441. 
[23]  Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic 
renal disease. J. Am. Soc. Nephrol. 1998;9:S16-23. 
[24]  Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in 
chronic renal disease. Am. J. Kidney Dis. 1998;32:S112-119. 
[25]  Pasch A, Farese S, Gräber S, et al. Nanoparticle-based test measures overall propensity 
for calcification in serum. J. Am. Soc. Nephrol. 2012;23:1744–1752. 
[26]  Smith ER, Ford ML, Tomlinson LA, et al. Serum calcification propensity predicts all-
cause mortality in predialysis CKD. J. Am. Soc. Nephrol. 2014;25:339–348. 
[27]  Pasch A, Block GA, Bachtler M, et al. Blood Calcification Propensity, Cardiovascular 
Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. Clin J 
Am Soc Nephrol. 2017;12:315–322. 
[28]  Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and 
calcium x phosphate product with mortality risk in chronic hemodialysis patients: a 
national study. Am. J. Kidney Dis. 1998;31:607–617. 
30 
 
[29]  Hou Y, Li X, Sun L, et al. Phosphorus and mortality risk in end-stage renal disease: A 
meta-analysis. Clin. Chim. Acta. 2017;474:108–113. 
[30]  Marks J, Lee GJ, Nadaraja SP, et al. Experimental and regional variations in Na+-
dependent and Na+-independent phosphate transport along the rat small intestine and 
colon. Physiol Rep. 2015;3. 
[31]  McHardy GJR, Parsons DS. The Absorption of Inorganic Phosphate from the Small 
Intestine of the Rat. Quarterly Journal of Experimental Physiology and Cognate Medical 
Sciences. 1956;41:398–409. 
[32]  Sabbagh Y, O’Brien SP, Song W, et al. Intestinal npt2b plays a major role in phosphate 
absorption and homeostasis. J. Am. Soc. Nephrol. 2009;20:2348–2358. 
[33]  Sabbagh Y, Giral H, Caldas Y, et al. Intestinal phosphate transport. Adv Chronic Kidney 
Dis. 2011;18:85–90. 
[34]  Hernando N, Myakala K, Simona F, et al. Intestinal Depletion of NaPi-IIb/Slc34a2 in 
Mice: Renal and Hormonal Adaptation. J. Bone Miner. Res. 2015;30:1925–1937. 
[35]  Knöpfel T, Himmerkus N, Günzel D, et al. Paracellular transport of phosphate along the 
intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2019;317:G233–G241. 
[36]  Hernando N, Wagner CA. Mechanisms and Regulation of Intestinal Phosphate 
Absorption. Compr Physiol. 2018;8:1065–1090. 
[37]  Katai K, Miyamoto K, Kishida S, et al. Regulation of intestinal Na+-dependent 
phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D3. 
Biochem. J. 1999;343 Pt 3:705–712. 
[38]  Forster IC, Hernando N, Biber J, et al. Proximal tubular handling of phosphate: A 
molecular perspective. Kidney Int. 2006;70:1548–1559. 
[39]  Lederer E, Wagner CA. Clinical aspects of the phosphate transporters NaPi-IIa and 
NaPi-IIb: mutations and disease associations. Pflugers Arch. 2019;471:137–148. 
[40]  Segawa H, Onitsuka A, Furutani J, et al. Npt2a and Npt2c in mice play distinct and 
synergistic roles in inorganic phosphate metabolism and skeletal development. Am. J. 
Physiol. Renal Physiol. 2009;297:F671-678. 
[41]  Beck L, Karaplis AC, Amizuka N, et al. Targeted inactivation of Npt2 in mice leads to 
severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc. Natl. 
Acad. Sci. U.S.A. 1998;95:5372–5377. 
[42]  Tenenhouse HS, Martel J, Gauthier C, et al. Differential effects of Npt2a gene ablation 
and X-linked Hyp mutation on renal expression of Npt2c. Am. J. Physiol. Renal Physiol. 
2003;285:F1271-1278. 
[43]  Biber J, Hernando N, Forster I. Phosphate transporters and their function. Annu. Rev. 
Physiol. 2013;75:535–550. 
[44]  Hu MC, Shi M, Moe OW. Role of αKlotho and FGF23 in regulation of type II Na-
dependent phosphate co-transporters. Pflugers Arch - Eur J Physiol. 2019;471:99–108. 
31 
 
[45]  Cunningham R, Biswas R, Brazie M, et al. Signaling pathways utilized by PTH and 
dopamine to inhibit phosphate transport in mouse renal proximal tubule cells. Am. J. 
Physiol. Renal Physiol. 2009;296:F355-361. 
[46]  Jacquillet G, Unwin RJ. Physiological regulation of phosphate by vitamin D, parathyroid 
hormone (PTH) and phosphate (Pi). Pflugers Arch. 2019;471:83–98. 
[47]  Shaman AM, Kowalski SR. Hyperphosphatemia Management in Patients with Chronic 
Kidney Disease. Saudi Pharm J. 2016;24:494–505. 
[48]  Kim HJ, Park M, Park HC, et al. Baseline FGF23 is Associated with Cardiovascular 
Outcome in Incident PD Patients. Perit Dial Int. 2016;36:26–32. 
[49]  Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D 
metabolism. Nat Rev Endocrinol. 2012;8:276–286. 
[50]  Yamamoto R, Minamizaki T, Yoshiko Y, et al. 1alpha,25-dihydroxyvitamin D3 acts 
predominately in mature osteoblasts under conditions of high extracellular phosphate to 
increase fibroblast growth factor 23 production in vitro. J. Endocrinol. 2010;206:279–
286. 
[51]  Hori M, Kinoshita Y, Taguchi M, et al. Phosphate enhances Fgf23 expression through 
reactive oxygen species in UMR-106 cells. J. Bone Miner. Metab. 2016;34:132–139. 
[52]  Ito N, Findlay DM, Anderson PH, et al. Extracellular phosphate modulates the effect of 
1α,25-dihydroxy vitamin D3 (1,25D) on osteocyte like cells. J. Steroid Biochem. Mol. 
Biol. 2013;136:183–186. 
[53]  Yu X, Sabbagh Y, Davis SI, et al. Genetic dissection of phosphate- and vitamin D-
mediated regulation of circulating Fgf23 concentrations. Bone. 2005;36:971–977. 
[54]  Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, 
calcium, and phosphorus in patients with chronic kidney disease: results of the study to 
evaluate early kidney disease. Kidney Int. 2007;71:31–38. 
[55]  Kates DM, Sherrard DJ, Andress DL. Evidence that serum phosphate is independently 
associated with serum PTH in patients with chronic renal failure. Am. J. Kidney Dis. 
1997;30:809–813. 
[56]  Raggi P, Kleerekoper M. Contribution of bone and mineral abnormalities to 
cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol. 
2008;3:836–843. 
[57]  Pande S, Ritter CS, Rothstein M, et al. FGF-23 and sFRP-4 in chronic kidney disease 
and post-renal transplantation. Nephron Physiol. 2006;104:p23-32. 
[58]  Miyamoto K, Segawa H, Ito M, et al. Physiological regulation of renal sodium-
dependent phosphate cotransporters. Jpn. J. Physiol. 2004;54:93–102. 
[59]  Rodriguez-Ortiz ME, Lopez I, Muñoz-Castañeda JR, et al. Calcium deficiency reduces 
circulating levels of FGF23. J. Am. Soc. Nephrol. 2012;23:1190–1197. 
32 
 
[60]  Carrillo-López N, Panizo S, Alonso-Montes C, et al. Direct inhibition of osteoblastic 
Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney 
disease. Kidney Int. 2016;90:77–89. 
[61]  Vervloet MG, van Ittersum FJ, Büttler RM, et al. Effects of dietary phosphate and 
calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol. 2011;6:383–389. 
[62]  Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J. Am. 
Soc. Nephrol. 2010;21:1427–1435. 
[63]  Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J. 
Clin. Invest. 2011;121:4393–4408. 
[64]  Verkaik M, Oranje M, Abdurrachim D, et al. High Fibroblast Growth Factor 23 
concentrations in experimental renal failure impair calcium handling in cardiomyocytes. 
Physiol Rep. 2018;6:e13591. 
[65]  Touchberry CD, Green TM, Tchikrizov V, et al. FGF23 is a novel regulator of 
intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am. J. 
Physiol. Endocrinol. Metab. 2013;304:E863-873. 
[66]  Faul C. FGF23 effects on the heart-levels, time, source, and context matter. Kidney Int. 
2018;94:7–11. 
[67]  Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic 
kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest. 
2012;122:2543–2553. 
[68]  Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. 
2015;16:165–174. 
[69]  Vervloet M. Renal and extrarenal effects of fibroblast growth factor 23. Nat Rev 
Nephrol. 2019;15:109–120. 
[70]  Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work 
Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, 
Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder 
(CKD-MBD). Kidney Int Suppl (2011). 2017;7:1–59. 
[71]  National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism 
and disease in chronic kidney disease. Am. J. Kidney Dis. 2003;42:S1-201. 
[72]  Shinaberger CS, Greenland S, Kopple JD, et al. Is Controlling Phosphorus by 
Decreasing Dietary Protein Intake Beneficial or Harmful in Individuals with Chronic 
Kidney Disease? Am J Clin Nutr. 2008;88:1511–1518. 
[73]  Shinaberger CS, Kilpatrick RD, Regidor DL, et al. Longitudinal associations between 
dietary protein intake and survival in hemodialysis patients. Am. J. Kidney Dis. 
2006;48:37–49. 
[74]  Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition-inflammation complex 




[75]  Moe SM, Zidehsarai MP, Chambers MA, et al. Vegetarian compared with meat dietary 
protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc 
Nephrol. 2011;6:257–264. 
[76]  Benini O, D’Alessandro C, Gianfaldoni D, et al. Extra-phosphate load from food 
additives in commonly eaten foods: a real and insidious danger for renal patients. J Ren 
Nutr. 2011;21:303–308. 
[77]  Savica V, Calò LA, Monardo P, et al. Salivary phosphorus and phosphate content of 
beverages: implications for the treatment of uremic hyperphosphatemia. J Ren Nutr. 
2009;19:69–72. 
[78]  Ritz E, Hahn K, Ketteler M, et al. Phosphate additives in food--a health risk. Dtsch 
Arztebl Int. 2012;109:49–55. 
[79]  Cannata-Andía JB, Martin KJ. The challenge of controlling phosphorus in chronic 
kidney disease. Nephrol. Dial. Transplant. 2016;31:541–547. 
[80]  Aniteli TM, de Siqueira FR, Dos Reis LM, et al. Effect of variations in dietary Pi intake 
on intestinal Pi transporters (NaPi-IIb, PiT-1, and PiT-2) and phosphate-regulating 
factors (PTH, FGF-23, and MEPE). Pflugers Arch. 2018;470:623–632. 
[81]  Cross HS, Debiec H, Peterlik M. Mechanism and regulation of intestinal phosphate 
absorption. Miner Electrolyte Metab. 1990;16:115–124. 
[82]  Hattenhauer O, Traebert M, Murer H, et al. Regulation of small intestinal Na-P(i) type 
IIb cotransporter by dietary phosphate intake. Am. J. Physiol. 1999;277:G756-762. 
[83]  Giral H, Caldas Y, Sutherland E, et al. Regulation of rat intestinal Na-dependent 
phosphate transporters by dietary phosphate. Am. J. Physiol. Renal Physiol. 
2009;297:F1466-1475. 
[84]  Stauber A, Radanovic T, Stange G, et al. Regulation of intestinal phosphate transport. II. 
Metabolic acidosis stimulates Na(+)-dependent phosphate absorption and expression of 
the Na(+)-P(i) cotransporter NaPi-IIb in small intestine. Am. J. Physiol. Gastrointest. 
Liver Physiol. 2005;288:G501-506. 
[85]  de Fornasari MLL, Dos Santos Sens YA. Replacing Phosphorus-Containing Food 
Additives With Foods Without Additives Reduces Phosphatemia in End-Stage Renal 
Disease Patients: A Randomized Clinical Trial. J Ren Nutr. 2017;27:97–105. 
[86]  Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia 
among patients with end-stage renal disease: a randomized controlled trial. JAMA. 
2009;301:629–635. 
[87]  Lou LM, Caverni A, Gimeno JA, et al. Dietary intervention focused on phosphate intake 
in hemodialysis patients with hyperphosphoremia. Clin. Nephrol. 2012;77:476–483. 
[88]  Schiavi SC, Tang W, Bracken C, et al. Npt2b deletion attenuates hyperphosphatemia 
associated with CKD. J. Am. Soc. Nephrol. 2012;23:1691–1700. 
[89]  Kaesler N, Goettsch C, Weis D, et al. Magnesium but not nicotinamide prevents vascular 
calcification in experimental uraemia. Nephrol. Dial. Transplant. 2019; 
34 
 
[90]  Wagner CA, Hernando N, Forster IC, et al. The SLC34 family of sodium-dependent 
phosphate transporters. Pflugers Arch. 2014;466:139–153. 
[91]  Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral 
metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns 
Study (DOPPS). Am. J. Kidney Dis. 2004;44:34–38. 
[92]  Filipski KJ, Sammons MF, Bhattacharya SK, et al. Discovery of Orally Bioavailable 
Selective Inhibitors of the Sodium-Phosphate Cotransporter NaPi2a (SLC34A1). ACS 
Med. Chem. Lett. 2018;9:440–445. 
[93]  Klar J. American Society of Nephrology | Kidney Week - Abstract Details [Internet]. 
ABSTRACT: TH-PO542. [cited 2019 Nov 29]. Available from: https://www.asn-
online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3230170. 
[94]  Thomas L, Xue J, Murali SK, et al. Pharmacological Npt2a Inhibition Causes 
Phosphaturia and Reduces Plasma Phosphate in Mice with Normal and Reduced Kidney 
Function. J. Am. Soc. Nephrol. 2019;30:2128–2139. 
[95]  Saito H. American Society of Nephrology | Kidney Week - Abstract Details [Internet]. 
ABSTRACT: TH-OR042. [cited 2019 Nov 30]. Available from: https://www.asn-
online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3234953. 
[96]  Spencer AG, Labonte ED, Rosenbaum DP, et al. Intestinal inhibition of the Na+/H+ 
exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci 
Transl Med. 2014;6:227ra36. 
[97]  Labonté ED, Carreras CW, Leadbetter MR, et al. Gastrointestinal Inhibition of Sodium-
Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular 
Calcification in CKD. J. Am. Soc. Nephrol. 2015;26:1138–1149. 
[98]  King AJ, Siegel M, He Y, et al. Inhibition of sodium/hydrogen exchanger 3 in the 
gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci 
Transl Med. 2018;10. 
[99]  Block GA, Rosenbaum DP, Leonsson-Zachrisson M, et al. Effect of Tenapanor on 
Serum Phosphate in Patients Receiving Hemodialysis. J. Am. Soc. Nephrol. 
2017;28:1933–1942. 
[100]  Block GA, Rosenbaum DP, Yan A, et al. Efficacy and Safety of Tenapanor in Patients 
with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 
Trial. J. Am. Soc. Nephrol. 2019;30:641–652. 
[101]  Block GA, Rosenbaum DP, Yan A, et al. The effects of tenapanor on serum fibroblast 
growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. Nephrol. 
Dial. Transplant. 2019;34:339–346. 
[102]  Taniguchi K, Terai K, Terada Y. Novel NaPi-IIb inhibitor ASP3325 inhibits 
phosphate absorption in intestine and reduces plasma phosphorus level in rats with renal 
failure. J Am Soc Nephrol (suppl). 2018;582A:FR-PO936. 
[103]  Larsson TE, Kameoka C, Nakajo I, et al. NPT-IIb Inhibition Does Not Improve 
Hyperphosphatemia in CKD. Kidney Int Rep. 2017;3:73–80. 
35 
 
[104]  Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia 
in Japan - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Oct 16]. Available 
from: https://clinicaltrials.gov/ct2/show/NCT02510274. 
[105]  Hasada N. American Society of Nephrology | Kidney Week - Abstract Details 
[Internet]. [cited 2019 Nov 30]. Available from: https://www.asn-
online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3231005. 
[106]  Moe S. American Society of Nephrology | Kidney Week - Abstract Details [Internet]. 
[cited 2019 Nov 30]. Available from: https://www.asn-
online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3229922. 
[107]  Eto N, Tomita M, Hayashi M. NaPi-mediated transcellular permeation is the dominant 
route in intestinal inorganic phosphate absorption in rats. Drug Metab. Pharmacokinet. 
2006;21:217–221. 
[108]  Katai K, Tanaka H, Tatsumi S, et al. Nicotinamide inhibits sodium-dependent 
phosphate cotransport activity in rat small intestine. Nephrol. Dial. Transplant. 
1999;14:1195–1201. 
[109]  Eto N, Miyata Y, Ohno H, et al. Nicotinamide prevents the development of 
hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter 
in rats with adenine-induced renal failure. Nephrol. Dial. Transplant. 2005;20:1378–
1384. 
[110]  Malhotra R, Katz R, Hoofnagle A, et al. The Effect of Extended Release Niacin on 
Markers of Mineral Metabolism in CKD. Clin J Am Soc Nephrol. 2018;13:36–44. 
[111]  Ix JH, Isakova T, Larive B, et al. Effects of Nicotinamide and Lanthanum Carbonate 
on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. J. 
Am. Soc. Nephrol. 2019;30:1096–1108. 
[112]  Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses 
hyperphosphatemia in hemodialysis patients. Kidney Int. 2004;65:1099–1104. 
[113]  Lenglet A, Liabeuf S, El Esper N, et al. Efficacy and safety of nicotinamide in 
haemodialysis patients: the NICOREN study. Nephrol. Dial. Transplant. 2017;32:870–
879. 
[114]  Cheng SC, Young DO, Huang Y, et al. A randomized, double-blind, placebo-
controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin 
J Am Soc Nephrol. 2008;3:1131–1138. 
[115]  Shahbazian H, Zafar Mohtashami A, Ghorbani A, et al. Oral nicotinamide reduces 
serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis 
patients: a double-blind randomized clinical trial. Nefrologia. 2011;31:58–65. 
[116]  El Borolossy R, El Wakeel LM, El Hakim I, et al. Efficacy and safety of nicotinamide 
in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. 
Pediatr. Nephrol. 2016;31:289–296. 
36 
 
[117]  Fissell RB, Karaboyas A, Bieber BA, et al. Phosphate binder pill burden, patient-
reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS. 
Hemodial Int. 2016;20:38–49. 
[118]  Van Camp YPM, Vrijens B, Abraham I, et al. Adherence to phosphate binders in 
hemodialysis patients: prevalence and determinants. J. Nephrol. 2014;27:673–679. 
[119]  Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate 
CKD. J. Am. Soc. Nephrol. 2012;23:1407–1415. 
[120]  Karamanidou C, Clatworthy J, Weinman J, et al. A systematic review of the 
prevalence and determinants of nonadherence to phosphate binding medication in 
patients with end-stage renal disease. BMC Nephrol. 2008;9:2. 
[121]  Ogata H, Fukagawa M, Hirakata H, et al. Design and baseline characteristics of the 
LANDMARK study. Clin Exp Nephrol. 2017;21:531–537. 
[122]  Sorribas V, Guillén N, Sosa C. Substrates and inhibitors of phosphate transporters: 
from experimental tools to pathophysiological relevance. Pflugers Arch. 2019;471:53–
65. 
[123]  Ketteler M, Zidek W, Karus M, et al. SP604PHARMACOLOGICAL PROPERTIES 
OF THE NOVEL NICOTINAMIDE MODIFIED RELEASE PREPARATION 
NOPHOS AS COMPLEMENTARY TREATMENT OPTION FOR 
HYPERPHOSPHATEMIA IN HEMODIALYSIS PATIENTS. Nephrol Dial Transplant 
[Internet]. 2019 [cited 2019 Sep 23];34. Available from: 
https://academic.oup.com/ndt/article/34/Supplement_1/gfz103.SP604/5514859. 







Figure 1. Different mechanisms of action of phosphate-lowering agents. Phosphate binders 
reduce the absorption of dietary phosphate in the intestine by forming a nonabsorbable 
compound in the lumen of the gastrointestinal tract that is excreted in the feces. Nicotinamide 
and ASP3325 inhibit sodium-dependent active intestinal phosphate absorption through the 
reduction of the intestinal NaPi2b phosphate transporter, whereas the pan-transporter inhibitor 
EOS789 targets both NaPi2b and the Pit1 and Pit2 transporters which are also localised in the 
intestine. Tenapanor reduces intestinal sodium and phosphate absorption by inhibiting the 
sodium/hydrogen ion-exchanger isoform 3 (NHE3), leading to intracellular proton 
accumulation and inducing a conformational change in tight junction proteins. This in turn 
decreases permeability to paracellular phosphate transport. 
Box 1. Unmet needs/important questions to be addressed in hyperphosphatemia 
No. Unmet need/question 
1 Long-term trials in larger patient cohorts are needed for nicotinamide and 
tenapanor. It is still unclear whether tenapanor can improve phosphate control 
compared to phosphate binders. 
2 Information is also lacking as to whether tenapanor may also act synergistically 
when used in combination with phosphate binders. 
7 The potential synergistic effect of tenapanor or nicotinamide with a phosphate 
binder remains to be fully understood and explored further in in-vivo studies and 
this has not been evaluated yet in CKD patients. 
3 Long-term trials examining the effect of nicotinamide as add-on to phosphate 
binders are missing.  
4 Novel mechanisms of action that have a pathophysiological rationale to address 
hyperphosphatemia are missing. 
5 The mechanisms regulating phosphate control in healthy individuals is poorly 
understood, particularly how paracellular phosphate uptake occurs. 
6 It is poorly understood as to why ASP3325 has been shown to be effective in 
preclinical studies but ineffective in patients. 
 
 
 
 

